Why did IQVIA (IQV) stock move recently?

On 7/23/2026, IQVIA moved +4.4% — No clear company-specific catalyst was identified for the 4.43% gain; the move appears to reflect pre-earnings positioning ahead of the July 28 Q2 report along with ongoing positive sentiment around data-driven growth and recent analyst upgrades. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is IQVIA (IQV) overvalued or fairly valued?

MarketChacha shows IQVIA's valuation in context — a trailing P/E of about 41.3, a forward P/E of about 18.8, a price-to-book of about 7.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does IQVIA's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.84×) from reported figures — education, not a rating.

What is IQVIA's revenue?

IQVIA reported revenue of $16.3B for FY2025, with net profit of $1.4B, per official filings.

What is the share price of IQVIA (IQV)?

IQVIA last traded at $267.77 (-1.4% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

IQVIA

IQV · NYSE · Healthcare · United States

Snapshot

TickerIQV

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees94,000

HeadquartersDurham, United States

Websitewww.iqvia.com

Filings tracked16

About IQVIA

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Who owns it

Insiders1.1%
Institutions98.9%
Public & other0.0%

1,559 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.84%
Harris Associates L.P.7.40%
Vanguard Capital Management LLC6.63%
State Street Corporation4.56%
Vanguard Portfolio Management LLC4.56%
JPMORGAN CHASE & CO3.73%
Artisan Partners Limited Partnership2.88%
Boston Partners2.71%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.84×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend9.1% → 8.3%

Margin has held broadly steady over the period — stable profitability.

Return on equity20.9%

Latest ROE of 20.9% — capital is generating a healthy return.

Growth qualityrev 4% · PAT 0%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $4.5B · EPS 3.65

Est. earnings growth +6.7%

Next fiscal year

Rev $18.5B · EPS 14.46

Est. earnings growth +11.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$16.3B

Net margin

8.3%

ROE

20.9%

Revenue CAGR (2y)

+4.3%

Profit CAGR (2y)

+0.1%

EPS (FY2025)

7.84

Net profit (FY2025)

$1.4B

Ask MarketChacha about IQV

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 23, 2026
No clear company-specific catalyst was identified for the 4.43% gain; the move appears to reflect pre-earnings positioning ahead of the July 28 Q2 report along with ongoing positive sentiment around data-driven growth and recent analyst upgrades.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about IQV

Why is IQVIA up ~12% today — the S&P 500's top gainer?c/usmarkets · 7/28/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$16.3B	$1.4B	7.84	8.3%	20.9%
FY2024	$15.4B	$1.4B	7.49	8.9%	22.6%
FY2023	$15.0B	$1.4B	7.29	9.1%	—

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$4.2B	$274.0M	1.61	6.6%
2025Q3	$4.1B	$331.0M	1.93	8.1%
2025Q2	$4.0B	$266.0M	1.54	6.6%
2025Q1	$3.8B	$249.0M	1.40	6.5%
2024Q3	$3.9B	$285.0M	1.55	7.3%
2024Q2	$3.8B	$363.0M	1.97	9.5%
2024Q1	$3.7B	$288.0M	1.56	7.7%
2023Q3	$3.7B	$303.0M	1.63	8.1%
2023Q2	$3.7B	$297.0M	1.59	8.0%
2023Q1	$3.7B	$289.0M	1.53	7.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/28/2026
8-K — Results of operations, Exhibits
SEC7/28/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC6/11/2026material
8-K — Other events, Exhibits
SEC6/4/2026material
8-K — Other events, Exhibits
SEC6/3/2026material
8-K — Other events, Exhibits
SEC5/7/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC4/23/2026material
10-K filing
SEC2/17/2026
8-K — Results of operations, Exhibits
SEC2/5/2026material

2025

8-K — Material agreement, Material financial obligation, Exhibits
SEC12/9/2025material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC11/5/2025material
8-K — Results of operations, Exhibits
SEC10/28/2025material
10-Q filing
SEC10/28/2025
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC9/2/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.